Concise Review: Clinical Relevance of Drug–Drug and Herb–Drug Interactions Mediated by the ABC Transporter ABCB1 (MDR1, P-glycoprotein)

ABC Transporters: From Microorganisms to Man

Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985 · see citing works

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

Juliano, R. L., & Ling, V. W. T. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,317 · see citing works

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

Thiebaut, F., TSURUO, T., Hamada, H., Gottesman, M. M., PASTAN, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777 · see citing works

Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. F., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,366 · see citing works

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

Schinkel, A. H., Smit, J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., Riele, H. T., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,284 · see citing works

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.

Cordon‐Cardo, C., O’Brien, J. P., Casals, D., Rittmann-Grauer, L., Biedler, J. L., Melamed, M. R., & Bertino, J. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.2.695 · Cited by 1,750 · see citing works

Expression of a multidrug-resistance gene in human tumors and tissues.

Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., & Pastan, I. H. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.265 · Cited by 1,545 · see citing works

Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.

Tsuruo, T., Iida, H., Tsukagoshi, S., & Sakurai, Y. (1981) · PubMed · Cited by 1,459 · see citing works

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview

Schinkel, A. H., & Jonker, J. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00169-2 · Cited by 1,427 · see citing works

Induction of phase I, II and III drug metabolism/transport by xenobiotics

Xu, C., Li, C. Y.-T., & Kong, A. T. (2005) · Archives of Pharmacal Research · doi:10.1007/bf02977789 · Cited by 1,272 · see citing works

P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

Schinkel, A. H., Wagenaar, E., Mol, C. A. A. M., & van Deemter, L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118699 · Cited by 1,265 · see citing works

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview

Schinkel, A. H., & Jonker, J. W. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.027 · Cited by 1,236 · see citing works

Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., & Borst, P. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118214 · Cited by 1,108 · see citing works

Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins

Gros, P., Croop, J. M., & Housman, D. E. (1986) · Cell · doi:10.1016/0092-8674(86)90594-5 · Cited by 1,043 · see citing works

Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell Lines

Kartner, N., Riordan, J. R., & Ling, V. W. T. (1983) · Science · doi:10.1126/science.6137059 · Cited by 1,005 · see citing works

St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor

Moore, L. B., Goodwin, B. J., Jones, S. A., Wisely, G. B., Serabjit‐Singh, C. J., Willson, T. M., Collins, J. L., & Kliewer, S. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130155097 · Cited by 946 · see citing works

Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins

Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A. A. M., van Deemter, L., Smit, J. J. M., van der Valk, M. A., Voordouw, A. C., Spits, H., van Tellingen, O., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4028 · Cited by 937 · see citing works

The Nuclear Pregnane X Receptor: A Key Regulator of Xenobiotic Metabolism

Kliewer, S. A., Goodwin, B. J., & Willson, T. M. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0038 · Cited by 922 · see citing works

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

Greiner, B., Eichelbaum, M. F., Fritz, P., Kreichgauer, H. P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917 · see citing works

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

Marzolini, C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.012 · Cited by 897 · see citing works

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., & van Tellingen, O. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2031 · Cited by 884 · see citing works

Indinavir concentrations and St John's wort

Piscitelli, S. C., Burstein, A. H., Chaitt, D. G., Alfaro, R. M., & Falloon, J. (2000) · The Lancet · doi:10.1016/s0140-6736(99)05712-8 · Cited by 873 · see citing works

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy

Wacher, V. J., Wu, C., & Benet, L. Z. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940130302 · Cited by 862 · see citing works

Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin

Geick, A., Eichelbaum, M. F., & Burk, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010173200 · Cited by 845 · see citing works

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

Synold, T. W., Dussault, I., & FORMAN, B. M. (2001) · Nature Medicine · doi:10.1038/87912 · Cited by 840 · see citing works

A Southwest Oncology Group study

Jenkins, T. R., Tangen, C. M., Macdonald, J. S., Weiss, G. R., Chapman, R. M., & Hantel, A. (1993) · Cited by 773 · see citing works

Association of Multidrug Resistance in Epilepsy with a Polymorphism in the Drug-Transporter GeneABCB1

Siddiqui, A. T. S., Kerb, R., Weale, M. E., Brinkmann, U., Smith, A. C., Goldstein, D. B., Wood, N. W., & Sisodiya, S. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021986 · Cited by 662 · see citing works

Acute heart transplant rejection due to Saint John's wort

Ruschitzka, F. T., Meier, P. J., Turina, M. I., Lüscher, T. F., & Noll, G. (2000) · The Lancet · doi:10.1016/s0140-6736(99)05467-7 · Cited by 644 · see citing works

Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)*1

Johne, A. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1053/cp.1999.v66.a101944 · Cited by 592 · see citing works

St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4

Dürr, D. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.112240 · Cited by 590 · see citing works

Piperine, a Major Constituent of Black Pepper, Inhibits Human P-glycoprotein and CYP3A4

Bhardwaj, R., Glaeser, H., Becquemont, L., Klotz, U. E., Gupta, S. K., & Fromm, M. F. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034728 · Cited by 555 · see citing works

Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.

Schuetz, E. G., Beck, W. T., & Schuetz, J. D. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08713-9 · Cited by 498 · see citing works

Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918

Kruijtzer, C. M. F., Beijnen, J. H., Rosing, H., Huinink, W. W. T. B., Schot, M. E., Jewell, R. C., Paul, E. M., & Schellens, J. H. M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.116 · Cited by 465 · see citing works

Effects of St. John's wort on irinotecan metabolism.

Mathijssen, R. H. J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1247 · Cited by 457 · see citing works

Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene.

Kroetz, D., Pauli-Magnus, C., Hodges, L. M., Huang, C. C., Kawamoto, M., Johns, S., Stryke, D., Ferrin, T., Deyoung, J., Taylor, T. R., et al. (2003) · Pharmacogenetics (London) · doi:10.1097/00008571-200308000-00006 · Cited by 438 · see citing works

Increased drug delivery to the brain by P-glycoprotein inhibition

Sadeque, A. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109156 · Cited by 426 · see citing works

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

Kempf, D. J., Marsh, K. C., Kumar, G. N., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.654 · Cited by 422 · see citing works

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

List, A. F., Kopecky, K. J., Willman, C. L., Head, D. R., Persons, D. L., Slovak, M. L., Dorr, R. T., Karanes, C., Hynes, H. E., Doroshow, J. H., et al. (2001) · Blood · doi:10.1182/blood.v98.12.3212 · Cited by 418 · see citing works

Reversal of Adriamycin Resistance by Verapamil in Human Ovarian Cancer

Rogan, A. M., Hamilton, T. C., Young, R. C., Klecker, R. W., & Ozols, R. F. (1984) · Science · doi:10.1126/science.6372095 · Cited by 396 · see citing works

The barrier function of CYP3A4 and P-glycoprotein in the small bowel

Watkins, P. B. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00041-0 · Cited by 395 · see citing works

Herbal Modulation of P‐Glycoprotein

Zhou, S., Lim, L. Y., & Chowbay, B. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-120028427 · Cited by 375 · see citing works

Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators

Hunter, J., Jepson, M. A., TSURUO, T., et al. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82429-2 · Cited by 370 · see citing works

Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo

Fellner, S., Bauer, B., Miller, D. S., Schaffrik, M., Fankhänel, M., Spruß, T., Bernhardt, G., Graeff, C., Färber, L., Gschaidmeier, H., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15451 · Cited by 359 · see citing works

Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo

Fellner, S., Bauer, B., Miller, D. S., Schaffrik, M., Fankhänel, M., Spruß, T., Bernhardt, G., Graeff, C., Färber, L., Gschaidmeier, H., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215451 · Cited by 359 · see citing works

Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure

Smit, J. W., Huisman, M. T., van Tellingen, O., WILTSHIRE, H. R., & Schinkel, A. H. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7963 · Cited by 352 · see citing works

The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients

Breedveld, P., Pluim, D., Cipriani, G., Wielinga, P. R., van Tellingen, O., Schinkel, A. H., & Schellens, J. H. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2416 · Cited by 352 · see citing works

Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction

Hébert, M. F., Roberts, J. P., Prueksaritanont, T., & Benet, L. Z. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.171 · Cited by 337 · see citing works

Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis

Schwab, M. G., Schaeffeler, E., Marx, C., Fromm, M. F., Kaskas, B., Metzler, J., Stange, E. F., Herfarth, H. H., Schöelmerich, J., Gregor, M., et al. (2003) · Gastroenterology · doi:10.1053/gast.2003.50010 · Cited by 323 · see citing works

Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs

Breedveld, P., Beijnen, J. H., & Schellens, J. H. M. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.009 · Cited by 323 · see citing works

Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice

Lankas, G. R., Wise, L. D., Cartwright, M. E., Pippert, T. R., & Umbenhauer, D. R. (1998) · Reproductive Toxicology · doi:10.1016/s0890-6238(98)00027-6 · Cited by 314 · see citing works

Effects of the Flavonoids Biochanin A, Morin, Phloretin, and Silymarin on P-Glycoprotein-Mediated Transport

Zhang, S., & Morris, M. E. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.044412 · Cited by 311 · see citing works

Genetic Polymorphisms of the HumanMDR1Drug Transporter

Schwab, M. G., Eichelbaum, M. F., & Fromm, M. F. (2003) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140233 · Cited by 310 · see citing works

Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.

Kilic, T., Alberta, J. A., Zdunek, P. R., Acar, M., Iannarelli, P., O'Reilly, T., Buchdunger, E., Black, P. M., & Stiles, C. D. (2000) · PubMed · Cited by 310 · see citing works

Contribution of adverse drug reactions to hospital admission of older patients

Mannesse, C. K. (2000) · Age and Ageing · doi:10.1093/ageing/29.1.35 · Cited by 304 · see citing works

Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols

Jodoin, J., Demeule, M., & Béliveau, R. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(01)00175-6 · Cited by 300 · see citing works

Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR

de Bruin, M., Miyake, K., Litman, T., Robey, R. W., & Bates, S. E. (1999) · Cancer Letters · doi:10.1016/s0304-3835(99)00182-2 · Cited by 298 · see citing works

Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine

Fattinger, K. E., Roos, M., Vergères, P., Holenstein, C., Kind, B., Masche, U., Stocker, D., Braunschweig, S., Kullak-Ublick, G. A., Galeazzi, R. L., et al. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00132.x · Cited by 296 · see citing works

Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells

Anuchapreeda, S., Leechanachai, P., Smith, M. M., Ambudkar, S. V., & Limtrakul, P. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01224-8 · Cited by 291 · see citing works

The interaction between St John's wort and an oral contraceptive

Hall, S. D. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.08.009 · Cited by 286 · see citing works

Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction

Westphal, K. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109797 · Cited by 285 · see citing works

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.

List, A. F., Spier, C. M., Greer, J. P., et al. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.9.1652 · Cited by 280 · see citing works

Drug interactions in oncology

Beijnen, J. H., & Schellens, J. H. M. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01528-1 · Cited by 278 · see citing works

Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated Efflux

Dai, H. I., Marbach, P., Lemaire, M., Hayes, M., & Elmquist, W. F. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045260 · Cited by 274 · see citing works

Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P‐glycoprotein

Kurata, Y., Ieiri, I., Kimura, M., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.126177 · Cited by 270 · see citing works

The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus.

Arceci, R. J., Croop, J. M., Horwitz, S. B., & Housman, D. E. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.12.4350 · Cited by 265 · see citing works

Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects

Dresser, G. K., Schwarz, U. I., Wilkinson, G. R., & Kim, R. B. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.10 · Cited by 261 · see citing works

Irinotecan pathway genotype analysis to predict pharmacokinetics.

Mathijssen, R. H. J., Marsh, S., Karlsson, M. O., Xie, R., Baker, S. D., Verweij, J., Sparreboom, A., & McLeod, H. L. (2003) · PubMed · Cited by 258 · see citing works

Effect of St John's wort on imatinib mesylate pharmacokinetics

Frye, R. F., Fitzgerald, S. M., Lagattuta, T. F., Hruska, M. W., & Egorin, M. J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.06.007 · Cited by 258 · see citing works

Pharmacokinetic Interactions of Drugs with St John’s Wort

Zhou, S., Chan, E., Pan, S. Q., Huang, M., & Lee, E. J. D. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104042632 · Cited by 256 · see citing works

MDR1 gene polymorphisms and disposition of the P‐glycoprotein substrate fexofenadine

Drescher, S., Schaeffeler, E., Hitzl, M., Hofmann, U., Schwab, M. G., Brinkmann, U., Eichelbaum, M. F., & Fromm, M. F. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01591.x · Cited by 249 · see citing works

MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients.

Illmer, T., Schuler, U. S., Thiede, C., Schwarz, U. I., Kim, R. B., Gotthard, S., Freund, D., Schäkel, U., Ehninger, G., & Schaich, M. A. (2002) · PubMed · Cited by 248 · see citing works

Quinidine-Digoxin Interaction

Doering, W. (1979) · New England Journal of Medicine · doi:10.1056/nejm197908233010803 · Cited by 247 · see citing works

Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.

Kemper, E. M., van Zandbergen, A. E., Cleypool, C. G. J., Mos, H. A., Boogerd, W. J., Beijnen, J. H., & van Tellingen, O. (2003) · PubMed · Cited by 243 · see citing works

Association of the P-Glycoprotein Transporter MDR1 C3435T Polymorphism with the Susceptibility to Renal Epithelial Tumors

Siegsmund, M. J., Brinkmann, U., Accent]ffeler, E. S. A., Weirich, G., Schwab, M. G., Eichelbaum, M. F., Fritz, P., Burk, O., Decker, J., Alken, P. M., et al. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000019412.87412.bc · Cited by 243 · see citing works

Herb–Drug Interactions in Oncology: Focus on Mechanisms of Induction

Meijerman, I., Beijnen, J. H., & Schellens, J. H. M. (2006) · The Oncologist · doi:10.1634/theoncologist.11-7-742 · Cited by 236 · see citing works

Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)

Greenberg, P. L., Lee, S. J., Advani, R. H., Tallman, M. S., Sikic, B. I., Letendre, L., Dugan, K., Lum, B. L., Chin, D. L., Dewald, G. W., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.048 · Cited by 234 · see citing works

Reversal of multidrug resistance by surfactants

Woodcock, D., Linsenmeyer, M. E., Chojnowski, G. M., Kriegler, A., Nink, V., Webster, L., & Sawyer, W. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.217 · Cited by 233 · see citing works

Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles

Breedveld, P., Zelcer, N., Pluim, D., Sönmezer, Ö., Tibben, M. M., Beijnen, J. H., Schinkel, A. H., van Tellingen, O., Borst, P., & Schellens, J. H. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-4062 · Cited by 230 · see citing works

Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein

Pauli‐Magnus, C., Rekersbrink, S., Klotz, U. E., et al. (2001) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-001-0489-7 · Cited by 230 · see citing works

Variable modulation of opioid brain uptake by P-glycoprotein in mice

Dagenais, C., Graff, C. L., & Pollack, G. M. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.08.027 · Cited by 220 · see citing works

Effect of St John's wort on the pharmacokinetics of fexofenadine

Wang, Z., Hamman, M. A., Huang, S. M., Lesko, L. J., & Hall, S. D. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.124080 · Cited by 214 · see citing works

The influence of verapamil on serum digoxin concentration.

Klein, H. O., Lang, R. M., Weiss, E. M., Segni, E. D., Libhaber, C. D., Guerrero, J., & Kaplinsky, E. (1982) · Circulation · doi:10.1161/01.cir.65.5.998 · Cited by 208 · see citing works

Polymorphism in the P-glycoprotein drug transporter MDR1 gene

Droździk, M., Białecka, M. A., liwiec, K. M., Honczarenko, K., Stankiewicz, J., & Sych, Z. (2003) · Pharmacogenetics · doi:10.1097/00008571-200305000-00004 · Cited by 207 · see citing works

Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.

Terwogt, J. M. M., Malingré, M. M., Beijnen, J. H., Huinink, W. W. T. B., Rosing, H., Koopman, F. J., van Tellingen, O., Swart, M., & Schellens, J. H. M. (1999) · PubMed · Cited by 205 · see citing works

The effect of rifampin administration on the disposition of fexofenadine

Hamman, M. A. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113697 · Cited by 204 · see citing works

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833

van Asperen, J., van Tellingen, O., Sparreboom, A., et al. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.530 · Cited by 203 · see citing works

A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression

Roberts, R. L., Joyce, P. R., Mulder, R., Begg, E., & Kennedy, M. A. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500099 · Cited by 201 · see citing works

Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein*

若杉, 博., Yano, I., Ito, T., et al. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90030-3 · Cited by 200 · see citing works

Coadministration of Cyclosporine Strongly Enhances the Oral Bioavailability of Docetaxel

Malingré, M. M., Richel, D. J., Beijnen, J. H., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1160 · Cited by 199 · see citing works

Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease.

Droździk, M., Białecka, M. A., Myśliwiec, K., Honczarenko, K., Stankiewicz, J., & Sych, Z. (2003) · PubMed · doi:10.1097/01.fpc.0000054087.48725.d9 · Cited by 189 · see citing works

Association ofCYP2C8, CYP3A4, CYP3A5, andABCB1Polymorphisms with the Pharmacokinetics of Paclitaxel

Henningsson, A., Marsh, S., Loos, W. J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1152 · Cited by 189 · see citing works

Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients

Bauer, S., Störmer, E., Johne, A., Krüger, H., Budde, K., Neumayer, H.-H., Roots, I., & Mai, I. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01759.x · Cited by 187 · see citing works

Inhibition of the CYP3A4‐mediated metabolism and P‐glycoprotein‐mediated transport of the HIV‐1 protease inhibitor saquinavir by grapefruit juice components

Eagling, Profit, & Back (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00052.x · Cited by 182 · see citing works

Effects of dietary chemopreventive phytochemicals on P-glycoprotein function

Nabekura, T., Kamiyama, S., & Kitagawa, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.12.081 · Cited by 180 · see citing works

Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors

Huisman, M. T., Smit, J. W., & Schinkel, A. H. (2000) · AIDS · doi:10.1097/00002030-200002180-00005 · Cited by 180 · see citing works

Expression polymorphism of the blood???brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease

Furuno, T., Landi, M.-T., Ceroni, M., Caporaso, N., Bernucci, I., Nappi, G., Martignoni, E., Schaeffeler, E., Eichelbaum, M., Schwab, M., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200210000-00004 · Cited by 178 · see citing works

Modulation of the blood–brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?

Kemper, E. M., Boogerd, W. J., Thuis, I., Beijnen, J. H., & van Tellingen, O. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.04.001 · Cited by 177 · see citing works

Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein

Westphal, K. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.107579 · Cited by 177 · see citing works

Itraconazole Decreases Renal Clearance of Digoxin

Jalava, K.-M., Partanen, J., & Neuvonen, P. J. (1997) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199712000-00001 · Cited by 176 · see citing works

Inhibition of Vinblastine Efflux Mediated by P-Glycoprotein by Grapefruit Juice Components in Caco-2 Cells.

Takanaga, H., Ohnishi, A., Matsuo, H., et al. (1998) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.21.1062 · Cited by 169 · see citing works

Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers*1

DING, R. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.02.008 · Cited by 169 · see citing works

Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients

Mai, I., Störmer, E., Bauer, S., Krüger, H., Budde, K., & Roots, I. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg002 · Cited by 169 · see citing works

Digoxin pharmacokinetics and MDR1 genetic polymorphisms

Verstuyft, C., Schwab, M. G., Schaeffeler, E., et al. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0567-5 · Cited by 167 · see citing works

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir*

Hsu, A., Granneman, G. R., Cao, G., et al. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90041-8 · Cited by 164 · see citing works

Clinical Studies with Modulators of Multidrug Resistance

Fisher, G. A., & Sikic, B. I. (1995) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30099-6 · Cited by 164 · see citing works

P-GLYCOPROTEIN SYSTEM AS A DETERMINANT OF DRUG INTERACTIONS: THE CASE OF DIGOXIN–VERAPAMIL

Verschraagen, M., Koks, C. H. W., Schellens, J. H. M., & Beijnen, J. H. (1999) · Pharmacological Research · doi:10.1006/phrs.1999.0535 · Cited by 159 · see citing works

Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco‐2 cells and on the activity of cytochrome P450 3A4

Ohnishi, A., Matsuo, H., Yamada, S., et al. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703433 · Cited by 158 · see citing works

Interaction between digoxin and calcium antagonists and antiarrhythmic drugs

Belz, G. G., Doering, W., Munkes, R., et al. (1983) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1983.55 · Cited by 157 · see citing works

A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study

Dalton, W. S., Crowley, J. J., Salmon, S., Grogan, T. M., Laufman, L. R., Weiss, G. R., & Bonnet, J. D. (1995) · Cancer · doi:10.1002/1097-0142(19950201)75:3 · Cited by 156 · see citing works

mdr-1Single Nucleotide Polymorphisms in Ovarian Cancer Tissue: G2677T/A Correlates with Response to Paclitaxel Chemotherapy

Gréen, H., Söderkvist, P., Rosenberg, P., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0950 · Cited by 156 · see citing works

Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg3

Kim, S., Kwon, H., Chi, D.-W., et al. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01446-6 · Cited by 155 · see citing works

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

Malingré, M. M., Beijnen, J. H., Rosing, H., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1543 · Cited by 153 · see citing works

Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome‐positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid

Takayama, N., Sato, N., O’Brien, S. G., Ikeda, Y., & Okamoto, S. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03881.x · Cited by 152 · see citing works

Effects of grapefruit juice and orange juice components on P‐glycoprotein‐ and MRP2‐mediated drug efflux

Honda, Y., Ushigome, F., Koyabu, N., et al. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706008 · Cited by 151 · see citing works

The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate

Smith, P. F., Bullock, J. M., Booker, B. M., Haas, C. E., Berenson, C. S., & Jusko, W. J. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.16.1508.50958 · Cited by 151 · see citing works

Grapefruit juice ingestion significantly reduces talinolol bioavailability

Schwarz, U. I., SEEMANN, D., Oertel, R., et al. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.11.111 · Cited by 149 · see citing works

Drug Interactions Between Antiretroviral Drugs and Comedicated Agents

de Maat, M. M. R., Ekhart, G. C., Huitema, A. D. R., Koks, C. H. W., Mulder, J. W., & Beijnen, J. H. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342030-00002 · Cited by 148 · see citing works

P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans

Schwarz, U. I., Gramatté, T., Krappweis, J., et al. (2000) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp38161 · Cited by 146 · see citing works

Phase III study of PSC‐833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95)

Friedenberg, W. R., Rué, M., Blood, E., et al. (2006) · Cancer · doi:10.1002/cncr.21666 · Cited by 146 · see citing works

Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids

Limtrakul, P., Anuchapreeda, S., & Buddhasukh, D. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-13 · Cited by 145 · see citing works

Effects of Rifampin on Tacrolimus Pharmacokinetics in Healthy Volunteers

Hébert, M. F., Fisher, R. M., Marsh, C. L., et al. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922007499 · Cited by 144 · see citing works

Unwanted pregnancy on self‐medication with St John's wort despite hormonal contraception

Schwarz, U. I., Büschel, B., & Kirch, W. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01716.x · Cited by 142 · see citing works

Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.

van Asperen, J., van Tellingen, O., van der Valk, M. A., et al. (1998) · PubMed · Cited by 140 · see citing works

Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation.

Chan, H. S. L., Deboer, G., Thiessen, J. J., et al. (1996) · PubMed · Cited by 138 · see citing works

St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism*1

TANNERGREN, C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.012 · Cited by 138 · see citing works

The Functional Role of P-Glycoprotein in the Blood–Brain Barrier

van Asperen, J., Mayer, U., van Tellingen, O., & Beijnen, J. H. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js9701364 · Cited by 138 · see citing works

Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.

Bardelmeijer, H. A., Ouwehand, M., Buckle, T., et al. (2002) · PubMed · Cited by 135 · see citing works

Active Transport of Fentanyl by the Blood-Brain Barrier

Henthorn, T. K., Liu, Y., Mahapatro, M., & Ng, K. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38239-4 · Cited by 135 · see citing works

Polymethoxylated Flavones in Orange Juice Are Inhibitors of P-glycoprotein but Not Cytochrome P450 3A4

Takanaga, H., Ohnishi, A., Yamada, S., et al. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39224-9 · Cited by 133 · see citing works

Functional role of P-glycoprotein in the human blood-placental barrier

Molsa, M., HEIKKINEN, T., Hakkola, J., HAKALA, K., Wallerman, O., Wadelius, M., Wadelius, C., & LAINE, K. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.04.014 · Cited by 132 · see citing works

Co-administration of cyclosporin enables oral therapy with paclitaxel

Terwogt, J. M. M., Beijnen, J. H., Huinink, W. W. T. B., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)24030-x · Cited by 129 · see citing works

Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol

Spahn-Langguth, H., & Langguth, P. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00191-3 · Cited by 124 · see citing works

Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein

Kemper, E. M., Verheij, M., Boogerd, W. J., Beijnen, J. H., & van Tellingen, O. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.024 · Cited by 123 · see citing works

Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer

Kafka, A., Sauer, G., Jaeger, C., et al. (2003) · International Journal of Oncology · doi:10.3892/ijo.22.5.1117 · Cited by 121 · see citing works

Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.

Bardelmeijer, H. A., Beijnen, J. H., Brouwer, K. R., Rosing, H., Nooijen, W. J., Schellens, J. H. M., & van Tellingen, O. (2000) · PubMed · Cited by 121 · see citing works

Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma

Belpomme, D., Gauthier, S., Pujade-Lauraine, É., Facchini, T., Goudier, M.-J., Krakowski, I., Netter-Pinon, G., Frénay, M., Gousset, C., MARIE, F.-N., et al. (2000) · Annals of Oncology · doi:10.1023/a:1026556119020 · Cited by 118 · see citing works

Pharmacologic approaches to reversing multidrug resistance.

Sikic, B. I. (1997) · PubMed · Cited by 117 · see citing works

Variation of Flavonoids and Furanocoumarins in Grapefruit Juices: A Potential Source of Variability in Grapefruit Juice−Drug Interaction Studies

de Castro, W. V., Mertens‐Talcott, S. U., Rubner, A., et al. (2005) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf0516944 · Cited by 116 · see citing works

Reversal of P-Glycoprotein-Mediated Multidrug Resistance by Protopanaxatriol Ginsenosides from Korean Red Ginseng

Choi, C.-H., Kang, G. J., & Min, Y. (2003) · Planta Medica · doi:10.1055/s-2003-38483 · Cited by 113 · see citing works

Effects of St. John's Wort (Hypericum perforatum) on Tacrolimus Pharmacokinetics in Healthy Volunteers

Hébert, M. F., Park, J. M., Chen, Y., Akhtar, S., & Larson, A. M. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003261078 · Cited by 113 · see citing works

Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview

Kruijtzer, C. M. F., Beijnen, J. H., & Schellens, J. H. M. (2002) · The Oncologist · doi:10.1634/theoncologist.7-6-516 · Cited by 110 · see citing works

Role of pharmacogenetics in irinotecan therapy

de Jong, F. A., de Jonge, M. J. A., Verweij, J., & Mathijssen, R. H. J. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.04.040 · Cited by 109 · see citing works

Determinants of the elimination of methotrexate and 7‐hydroxy‐methotrexate following high‐dose infusional therapy to cancer patients

Joerger, M., Huitema, A. D. R., van den Bongard, H. J. G. D., et al. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02513.x · Cited by 107 · see citing works

Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial.

Wishart, G. C., Bissett, D., Paul, J., Jodrell, D. I., Harnett, A. N., Habeshaw, T., Kerr, D. J., Macham, M. A., Soukop, M., & Leonard, R. C. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.9.1771 · Cited by 102 · see citing works

Inhibition of P-glycoprotein by orange juice components, polymethoxyflavones in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells

Ikegawa, T., Ushigome, F., Koyabu, N., et al. (2000) · Cancer Letters · doi:10.1016/s0304-3835(00)00549-8 · Cited by 101 · see citing works

Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance

Sadzuka, Y., Sugiyama, T., & Sonobe, T. (2000) · Toxicology Letters · doi:10.1016/s0378-4274(99)00290-8 · Cited by 99 · see citing works

Effects of curcumin on P-glycoprotein in primary cultures of rat hepatocytes

Romiti, N., Tongiani, R., Cervelli, F., et al. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00216-1 · Cited by 98 · see citing works

Low concentrations of STI571 in the cerebrospinal fluid: a case report

Petzer, A. L., Gunsilius, E., Hayes, M., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03523.x · Cited by 98 · see citing works

Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40

Tayrouz, Y., Ding, R., Burhenne, J., et al. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00059-6 · Cited by 95 · see citing works

Diltiazem Increases Tacrolimus Concentrations

Hébert, M. F., & Lam, A. Y. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18356 · Cited by 95 · see citing works

Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer

Zhou, Q. S., Sparreboom, A., Tan, E.-H., Cheung, Y., Lee, A., Poon, D. Y. H., Lee, E. J. D., & Chowbay, B. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02330.x · Cited by 94 · see citing works

Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC–HOVON randomized phase III study (06914)

Sonneveld, P., Suciu, S., Weijermans, P., Beksaç, M., Neuwirtová, R., Solbu, G., Lokhorst, H. M., der Lelie, J. V., Döhner, H., Gerhartz, H., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03171.x · Cited by 93 · see citing works

Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study

Millward, M. J., Cantwell, B. M. J., Munro, N. C., Robinson, A. G., Corris, P. A., & Harris, A. L. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.189 · Cited by 91 · see citing works

Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833

Chico, I. M., Kang, M. H., Bergan, R. C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.832 · Cited by 90 · see citing works

Inhibition of P-Glycoprotein Transport Function by Grapefruit Juice Psoralen

Wang, E., Casciano, C. N., Clement, R. P., et al. (2001) · Pharmaceutical Research · doi:10.1023/a:1011089924099 · Cited by 89 · see citing works

Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia

Solary, É., Drénou, B., Campos, L., de Crémoux, P., Mugneret, F., Moreau, P., Lioure, B., Falkenrodt, A., Witz, B., Bernard, M., et al. (2003) · Blood · doi:10.1182/blood-2002-11-3419 · Cited by 87 · see citing works

Pharmacogenomics of MDR1 / ABCB1 Gene: the Influence on Risk and Clinical Outcome of Haematological Malignancies

Jamroziak, K., & Robak, T. (2004) · Hematology · doi:10.1080/10245330310001638974 · Cited by 86 · see citing works

Dose‐dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL

Martin‐Facklam, M., Burhenne, J., Ding, R., et al. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01595.x · Cited by 86 · see citing works

The Role of P-Glycoprotein and Organic Anion-Transporting Polypeptides in Drug Interactions

DuBuske, L. M. (2005) · Drug Safety · doi:10.2165/00002018-200528090-00004 · Cited by 84 · see citing works

P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy

Sankatsing, S. U. C., Beijnen, J. H., Schinkel, A. H., Lange, J. M. A., & Prins, J. M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1073-1081.2004 · Cited by 83 · see citing works

Cyclosporin‐erythromycin interaction in renal transplant patients.

Gupta, S., Bakran, A., Johnson, R. W. G., et al. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb05396.x · Cited by 81 · see citing works

Quinidine as a Probe for the Role of P‐Glycoprotein in the Intestinal Absorption and Clinical Effects of Fentanyl

Kharasch, E. D., Hoffer, C., Altuntas, T. G., et al. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003262075 · Cited by 80 · see citing works

Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists

Babaoglu, M. O., Bayar, B., AYNACIOGLU, A., et al. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.08.015 · Cited by 79 · see citing works

Effect of grapefruit juice intake on etoposide bioavailability

Reif, S., Nicolson, M. C., Bisset, D., et al. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0495-9 · Cited by 79 · see citing works

Enhanced Cardiac Effect of Digoxin During Quinidine Treatment

Leahey, E. B. (1979) · Archives of Internal Medicine · doi:10.1001/archinte.1979.03630420015008 · Cited by 78 · see citing works

Reversal of cancer multidrug resistance by green tea polyphenols

Mei, Y., Qian, F., Wei, D., et al. (2004) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357044364 · Cited by 74 · see citing works

Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies

Fracasso, P. M., Goldstein, L. J., de Alwis, D. P., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0452 · Cited by 70 · see citing works

A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer

Milroy, R. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.433 · Cited by 68 · see citing works

EFFECT OF PROTOTYPICAL INDUCING AGENTS ON P-GLYCOPROTEIN AND CYP3A EXPRESSION IN MOUSE TISSUES

Matheny, C. J., Ali, R. Y., Yang, X., et al. (2004) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)02985-4 · Cited by 68 · see citing works

Phase II and Pharmacologic Study of Weekly Oral Paclitaxel Plus Cyclosporine in Patients With Advanced Non–Small-Cell Lung Cancer

Kruijtzer, C. M. F., Schellens, J. H. M., Mezger, J. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.058 · Cited by 59 · see citing works

Impact of omeprazole on the plasma clearance of methotrexate

Reid, T., Yuen, A. R., Catolico, M., et al. (1993) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686028 · Cited by 56 · see citing works

Severe myalgia from an interaction between treatments with pantoprazole and methotrexate

Tröger, U., Stötzel, B., Martens-Lobenhoffer, J., et al. (2002) · BMJ · doi:10.1136/bmj.324.7352.1497 · Cited by 53 · see citing works

Erythromycin enhances the absorption of cyclosporin.

Gupta, S. K., Bakran, A., Johnson, R. W. G., & Rowland, M. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03320.x · Cited by 53 · see citing works

Digoxin toxicity due to interaction of digoxin with erythromycin.

Maxwell, D. L., Gilmour-White, S. K., & Hall, M. R. (1989) · BMJ · doi:10.1136/bmj.298.6673.572 · Cited by 53 · see citing works

A Model for the Prediction of Digoxin-Drug Interactions at the Renal Tubular Cell Level

Woodland, C., Ito, S., & Koren, G. (1998) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199804000-00002 · Cited by 49 · see citing works

Modulation of Digoxin Transport Across Caco-2 Cell Monolayers by Citrus Fruit Juices: Lime, Lemon, Grapefruit, and Pummelo

Xu, J., Go, M., & Lim, L. Y. (2003) · Pharmaceutical Research · doi:10.1023/a:1022254617664 · Cited by 48 · see citing works

Carotenoids and their metabolites are naturally occurring activators of gene expression via the pregnane X receptor

�, R. R., Sczech, R., Landes�, N., et al. (2004) · European Journal of Nutrition · doi:10.1007/s00394-004-0475-1 · Cited by 47 · see citing works

Quinidine and Digoxin An Important Interaction

Bigger, J. T., & Leahey, E. B. (1982) · Drugs · doi:10.2165/00003495-198224030-00003 · Cited by 47 · see citing works

Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer

Kruijtzer, C. M. F., Boot, H., Beijnen, J. H., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg078 · Cited by 47 · see citing works

New approaches in cancer treatment

Sikic, B. I. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_6.s149 · Cited by 46 · see citing works

Multidrug resistance: clinical relevance in acute leukemia.

List, A. F. (1993) · PubMed · Cited by 46 · see citing works

Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer

Yamaguchi, H., Hishinuma, T., Endo, N., Tsukamoto, H., Kishikawa, Y., Masugi, S. A. T. O., MURAI, Y., Hiratsuka, M., Ito, K., Okamura, C., et al. (2006) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00593.x · Cited by 45 · see citing works

Differential Bidirectional Transfer of Indinavir in the Isolated Perfused Human Placenta

Sudhakaran, S. S., Ghabrial, H., Nation, R. L., Kong, D. C. M., Gude, N. M., Angus, P., & Rayner, C. R. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.1023-1028.2005 · Cited by 44 · see citing works

Incidence of lethal adverse drug reactions in the comprehensive hospital drug monitoring, a 20-year survey, 1974-1993, based on the data of Berne/St. Gallen

Zoppi, M., Braunschweig, S., Kuenzi, U. P., et al. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000158 · Cited by 40 · see citing works

Antineoplastic Agents Drug Interactions of Clinical Significance

van Meerten, E., Verweij, J., & Schellens, J. H. M. (1995) · Drug Safety · doi:10.2165/00002018-199512030-00003 · Cited by 38 · see citing works

Interaction Between Digoxin and Propafenone

Calvo, M. V. M., Martín‐Suárez, A., Luengo, C. M., et al. (1989) · Therapeutic Drug Monitoring · doi:10.1097/00007691-198901000-00003 · Cited by 38 · see citing works

The Digoxin-Propafenone Interaction: Characterization of a Mechanism Using Renal Tubular Cell Monolayers

Woodland, C., Verjee, Z. H., Giesbrecht, E. E., et al. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37024-7 · Cited by 38 · see citing works

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer

Helgason, H. H., Kruijtzer, C. M. F., Huitema, A. D. R., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603332 · Cited by 38 · see citing works

St. John’s Wort Modulates the Toxicities and Pharmacokinetics of CPT-11 (Irinotecan) in Rats

Hu, Z., Yang, X., Ho, P. C., Chan, E., Chan, S. Y., Xu, C., Li, X., Zhu, Y. Z., Duan, W., Chen, X., et al. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-4585-0 · Cited by 37 · see citing works

Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response

Wada, M. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.06.050 · Cited by 35 · see citing works

Erythromycin-Induced Digoxin Toxicity

Morton, M. R., & Cooper, J. W. (1989) · DICP · doi:10.1177/106002808902300908 · Cited by 31 · see citing works

A Pilot Phase II Trial of Valspodar Modulation of Multidrug Resistance to Paclitaxel in the Treatment of Metastatic Carcinoma of the Breast (E1195): A Trial of the Eastern Cooperative Oncology Group

Carlson, R. W., O’Neill, A., Goldstein, L. J., et al. (2006) · Cancer Investigation · doi:10.1080/07357900600981349 · Cited by 29 · see citing works

Possible Prediction of the Efficiency of Chemotherapy in Patients with Lymphoproliferative Diseases Based on MDR1 Gene G2677T and C3435T Polymorphisms

Горева, О. Б., Grishanova, A. Y., Mukhin, O. V., et al. (2003) · Bulletin of Experimental Biology and Medicine · doi:10.1023/a:1026331326648 · Cited by 28 · see citing works

Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia.

Jamroziak, K., Balcerczak, E., Cebula‐Obrzut, B., et al. (2006) · PubMed · Cited by 27 · see citing works

Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer

Yamaguchi, H., Hishinuma, T., Endo, N., et al. (2006) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-00009577-200605000-00004 · Cited by 23 · see citing works

Digoxin toxicity and ritonavir

Phillips, E. J., Rachlis, A., & Ito, S. (2003) · AIDS · doi:10.1097/00002030-200307040-00026 · Cited by 17 · see citing works

Digoxin toxicity and ritonavir: a drug interaction mediated through p-glycoprotein?

Phillips, E. J., Rachlis, A., & Ito, S. (2003) · PubMed · doi:10.1097/01.aids.0000072673.21517.d6 · Cited by 14 · see citing works

Nitrogen-containing ecdysteroid derivatives vs. multi-drug resistance in cancer: Preparation and antitumor activity of oximes, oxime ethers and a lactam

Vágvölgyi, M., Martins, A., Kulmány, Á., Zupkó, I., Gáti, T., Simon, A., Tóth, G., & Hunyadi, A. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.12.032 · Cited by 37 · see citing works

Melatonin Interaction Resulting in Severe Sedation

Foster, B. C., Cvijovic, K., Boon, H. S., Tam, T. W., Liu, R., Murty, M., Vu, D., Jaeger, W., Tsuyuki, R. T., Barnes, J., et al. (2015) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3ss35 · Cited by 17 · see citing works

Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2

Shukla, S., Sauna, Z. E., & Ambudkar, S. V. (2007) · Leukemia · doi:10.1038/sj.leu.2404897 · Cited by 96 · see citing works

A primer on the mechanics of P-glycoprotein the multidrug transporter

Hennessy, M., & Spiers, P. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2006.10.007 · Cited by 201 · see citing works

Intestinal efflux transporters and drug absorption

Murakami, T., & Takano, M. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.7.923 · Cited by 201 · see citing works

Cholesterol Interaction with the Daunorubicin Binding Site of P-Glycoprotein

Wang, E., Casciano, C. N., Clement, R. P., et al. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3554 · Cited by 55 · see citing works

A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro

Fahmi, O. A., Maurer, T. S., Kish, M., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018663 · Cited by 204 · see citing works